Bayer (BAYN) Receives Buy Rating from Citigroup

Bayer (FRA:BAYN)‘s stock had its “buy” rating restated by analysts at Citigroup in a note issued to investors on Wednesday.

Several other equities research analysts have also issued reports on BAYN. Warburg Research set a €121.00 ($144.05) price target on shares of Bayer and gave the stock a “neutral” rating in a research note on Thursday, January 11th. Independent Research set a €120.00 ($142.86) price target on shares of Bayer and gave the stock a “neutral” rating in a research note on Friday, January 12th. Sanford C. Bernstein set a €129.00 ($153.57) price target on shares of Bayer and gave the stock a “buy” rating in a research note on Wednesday. Jefferies Group set a €125.00 ($148.81) price target on shares of Bayer and gave the stock a “buy” rating in a research note on Tuesday. Finally, UBS Group restated a “buy” rating on shares of Bayer in a research note on Monday. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of €121.71 ($144.90).

Shares of Bayer (FRA:BAYN) traded up €0.60 ($0.71) during mid-day trading on Wednesday, hitting €104.08 ($123.90). 2,842,251 shares of the stock traded hands. Bayer has a 12 month low of €100.60 ($119.76) and a 12 month high of €123.82 ($147.40). The stock has a market cap of $85,980.00 and a price-to-earnings ratio of 27.90.

TRADEMARK VIOLATION NOTICE: “Bayer (BAYN) Receives Buy Rating from Citigroup” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2018/01/19/bayer-bayn-receives-buy-rating-from-citigroup.html.

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply